Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Successful Long Term Therapeutic Expression of Factor VIII in Hemophilia A Dogs After Administration of AAV-cFVIII Using a Two-Chain or Single Chain Delivery Approach.

Denise E. Sabatino, Ph.D., Ekaterina Altynova, B.S., Amy M. Lange, B.S., Shangzhen Zhou, M.D., Elizabeth P. Merricks, B.S., Aaron M. Dillow, B.S., Timothy C. Nichols, M.D., Valder R. Arruda, M.D., Ph.D., Haig H. Kazazian, Jr., M.D.

Blood (2009) 114 (22): 546.

https://doi.org/10.1182/blood.V114.22.546.546

Published: 2009

Journal Articles

Recombinant canine B-domain–deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model

Denise E. Sabatino, Christian Furlan Freguia, Raffaella Toso, Andrey Santos, Elizabeth P. Merricks, Haig H. Kazazian, Jr, Timothy C. Nichols, Rodney M. Camire, Valder R. Arruda

Blood (2009) 114 (20): 4562–4565.

https://doi.org/10.1182/blood-2009-05-220327

Published: 2009

Includes: Supplemental data

Journal Articles

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype

Rita Sarkar, Renee Tetreault, Guangping Gao, Lili Wang, Peter Bell, Randy Chandler, James M. Wilson, Haig H. Kazazian, Jr

Blood (2004) 103 (4): 1253–1260.

https://doi.org/10.1182/blood-2003-08-2954

Published: 2004

Journal Articles

Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin

Steven S. Fakharzadeh, Yue Zhang, Rita Sarkar, Haig H. Kazazian, Jr

Blood (2000) 95 (9): 2799–2805.

https://doi.org/10.1182/blood.V95.9.2799.009k23_2799_2805

Published: 2000

Journal Articles

The Molecular Basis for Cross-Reacting Material–Positive Hemophilia A Due to Missense Mutations Within the A2-Domain of Factor VIII

Kagehiro Amano, Rita Sarkar, Susan Pemberton, Geoffrey Kemball-Cook, Haig H. Kazazian, Jr, Randal J. Kaufman

Blood (1998) 91 (2): 538–548.

https://doi.org/10.1182/blood.V91.2.538

Published: 1998

NARROW

Successful Long Term Therapeutic Expression of Factor VIII in Hemophilia A Dogs After Administration of AAV-cFVIII Using a Two-Chain or Single Chain Delivery Approach.

Recombinant canine B-domain–deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype

Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin

The Molecular Basis for Cross-Reacting Material–Positive Hemophilia A Due to Missense Mutations Within the A2-Domain of Factor VIII

Email alerts

ASH Publications

American Society of Hematology

Successful Long Term Therapeutic Expression of Factor VIII in Hemophilia A Dogs After Administration of AAV-cFVIII Using a Two-Chain or Single Chain Delivery Approach.

Recombinant canine B-domain–deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model

Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype

Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin

The Molecular Basis for Cross-Reacting Material–Positive Hemophilia A Due to Missense Mutations Within the A2-Domain of Factor VIII

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only